“…The dysregulation of certain enzymes and/or specific antibodies, both hypo-or overexpression, in certain pathological states or diseased tissues can also be used for triggering the therapeutic cargo release from MSNs. [93], [94], [95], [96], [97], [98], [99], [100], [101], [102] Similarly, the change in redox potential as it happens in tumor tissues where the glutathione concentration can be four times higher than in healthy tissues, can be employed to develop responsive MSNs. [10], [103][104], [105], [106], [107], [108], [109], [110], [111], [112] On the other hand, external stimuli are those than can be activated remotely by the clinician, who is under control at all times.…”